Insider Selling: Anthem (NASDAQ:ANTX) Insider Sells $11,925.72 in Stock

Anthem, Inc. (NASDAQ:ANTX) insider Joshua Eizen sold 2,826 shares of Anthem stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $4.22, for a total transaction of $11,925.72. Following the completion of the transaction, the insider owned 207,546 shares of the company’s stock, valued at $875,844.12. The trade was a 1.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anthem Price Performance

NASDAQ ANTX opened at $4.00 on Monday. The firm has a market cap of $150.94 million, a P/E ratio of -3.74 and a beta of -0.93. The company’s 50 day moving average is $4.74 and its 200-day moving average is $4.11. Anthem, Inc. has a 12-month low of $1.00 and a 12-month high of $7.19.

Anthem (NASDAQ:ANTX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter.

Institutional Trading of Anthem

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Citizens Financial Group Inc. RI bought a new position in shares of Anthem in the second quarter worth $1,443,000. ADAR1 Capital Management LLC purchased a new stake in shares of Anthem in the first quarter worth $47,000. OMERS ADMINISTRATION Corp bought a new stake in Anthem during the first quarter valued at $54,000. Velan Capital Investment Management LP bought a new stake in Anthem during the second quarter valued at $194,000. Finally, Seven Fleet Capital Management LP bought a new stake in Anthem during the first quarter valued at $683,000. Institutional investors own 90.47% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on ANTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Anthem in a research report on Friday, October 2nd. Guggenheim started coverage on Anthem in a research note on Monday, July 20th. They issued a “buy” rating and a $9.00 target price for the company. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.00.

About Anthem

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.